The replicate confirmatory KALOS and LOGOS trials evaluated BGF in participants with severe asthma inadequately controlled with standard of care.

The review extension was needed as the FDA required time to review Cytokinetics’ proposed Risk Evaluation and Mitigation Strategy (REMS).